Gamida Cell Ltd. (GMDA) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Jerusalem, 以色列. 现任CEO为 Abigail L. Jenkins.
GMDA 拥有 IPO日期为 2018-10-26, 143 名全职员工, 在 NASDAQ Global Market, 市值为 $4.34M.
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
